StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
S66.AX$0.14-19.44%
Fair $0.14+0.0%

S66.AX

Star Combo Pharma Limited

Consumer Defensive / Household & Personal ProductsASX

$0.14

-0.04 (-19.44%)

Fairly Valued+0.0%Fair Value $0.14Fund rank 29/100 · Data gapFallback financials|
SA 38/D
F-Score: 6/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 33% · confianza 22%

FCF escenarios

weak_data · normalized FCF $-1.8M · quality 62.0/100

Data gap 29/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 28/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

38/100

D

Piotroski

6/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. ROE is 2.2%, below the 5% threshold
Thesis & Journal · S66.AXLocal privado en este navegador · Star Combo Pharma Limited
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$20M

P/E

3.6x

↓

EV/EBITDA

5.8x

↓

ROE

2.2%

↓

Gross Margin

28.5%

↑

Debt/Equity

0.12

↓
52-Week Range$0
$0$0

TradingView lightweight chart

S66.AX price, volumen y niveles de valoración

Último $0.145Periodo -81.6%
Fair value: $0.145

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2021–2024 · 3 años de histórico normalizado

Revenue CAGR

-0.9%

FCF CAGR

—

FCF margin

-6.8%

FCF / Net income

-2.35x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $26.0M · net income $747330.0 · FCF $-1.8M

2021-FY → 2024-FY

Gross margin

28.5%+11.2% pts

Operating margin

-0.4%+9.9% pts

Net margin

2.9%+32.3% pts

FCF margin

-6.8%+19.2% pts
MetricTTM
2024
2023
2022
2021
Income Statement
Revenue$26.0M$26.0M$24.7M$22.9M$26.7M
Net Income$747330.00$747330.00$-4.0M$-696349.00$-7.9M
EBITDA$2.8M$2.8M$-2.5M$-126706.00$-6.4M
EPS0.010.01-0.03-0.01—
Gross Margin28.5%28.5%21.8%24.5%17.2%
Operating Margin-0.4%-0.4%3.4%-4.1%-10.2%
Net Margin2.9%2.9%-16.2%-3.0%-29.5%
Balance Sheet
Debt/Equity0.120.120.130.120.09
Current Ratio6.646.64———
Cash Flow
Free Cash Flow$-1.8M$-1.8M$-851831.00$-6.8M$-6.9M
Returns
ROE2.2%2.2%-12.1%-2.0%-21.8%
Valuation
P/E3.633.63———
EV/EBITDA5.835.83———
P/B0.590.590.370.590.95
Growth & Yield
Revenue Growth5.3%5.3%8.0%-14.4%—
EPS Growth118.3%118.3%-500.0%——
Dividend Yield2.5%2.5%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

32.7%

muy exigente

EPS terminal req.

$0.01

Spread vs growth

85.6%

5Y implied EPS CAGR

23.1%

exigente

EPS terminal req.

$0.02

Spread vs growth

95.2%

10Y implied EPS CAGR

16.4%

exigente

EPS terminal req.

$0.03

Spread vs growth

102.0%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -6.8%

Total return

-6.8%

Start / end P/E

n/dx → n/dx

EPS bridge

-0.03 → 0.01

Residual

-9.4%

EPS growthn/d
Multiple reratingn/d
Dividend+2.5%
Residual / FX / buybacks / cross-term-9.4%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.